Acceptable performance of blood biomarker tests of amyloid pathology — recommendations from the Global CEO Initiative on Alzheimer’s Disease

Anti-amyloid treatments for early symptomatic Alzheimer disease have recently become clinically available in some countries, which has greatly increased the need for biomarker confirmation of amyloid pathology. Blood biomarker (BBM) tests for amyloid pathology are more acceptable, accessible and scalable than amyloid PET or cerebrospinal fluid (CSF) tests, but have highly variable levels of performance. The Global CEO Initiative on Alzheimer’s Disease convened a BBM Workgroup to consider the minimum acceptable performance of BBM tests for clinical use. Amyloid PET status was identified as the reference standard. For use as a triaging test before subsequent confirmatory tests such as amyloid PET or CSF tests,…

• UD
  U.S. Department of Defense
• AA
  Alzheimer's Association

  Award: 100010434
• LL
  Larry L. Hillblom Foundation
• RJ
  Robert J. and Claire Pasarow Foundation
• EL
  Eli Lilly and Company
• P
  Pfizer
• S
  Sanofi
• CD
  California Department of Public Health
• B
  Biogen
• UO
  University of Southern California
• C
  Celgene
• VU
  Vanderbilt University
• FH
  F. Hoffmann-La Roche
• VU
  Vanderbilt University Medical Center
• AP
  ACADIA Pharmaceuticals
• FU
  Fujirebio US
• P
  Prothena
• IP
  International Progressive MS Alliance
• EC
  European Commission

  Awards: 100010434, 847648, 948677, 101034344, 831434, 860197, ID 100010434
• AC
  Australian Catholic University
• Z
  ZonMw

  Award: 10510032120003
• NO
  Nederlandse Organisatie voor Wetenschappelijk Onderzoek

  Award: 100010434
• E
  Eisai
• NN
  Novo Nordisk
• AN
  Alzheimer Nederland
• SH
  Siemens Healthineers
• G
  Grifols
• NI
  National Institutes of Health

  Awards: 100010434, R01 AG070941, R01 AG063819
• G
  Genentech
• AR
  Avid Radiopharmaceuticals
• ID
  Instituto de Salud Carlos III

  Awards: PI22/00456, PI19/00155
• NI
  National Institute of Neurological Disorders and Stroke